• Loading stock data…

Bristol-Myers Squibb

Evaluating the Merits of AVEO’s Potential Purchase

At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase

Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market

Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market

GALT is Primed for Acquisition or Partnership

Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for  Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership